Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Equity Ratio (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Equity Ratio for 9 consecutive years, with 0.89 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 1.05% to 0.89 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.89 through Dec 2025, down 1.05% year-over-year, with the annual reading at 0.89 for FY2025, 1.05% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.89 at Denali Therapeutics, up from 0.88 in the prior quarter.
  • The five-year high for Equity Ratio was 0.92 in Q2 2024, with the low at 0.66 in Q3 2022.
  • Average Equity Ratio over 5 years is 0.81, with a median of 0.88 recorded in 2025.
  • The sharpest move saw Equity Ratio dropped 15.33% in 2021, then soared 36.82% in 2023.
  • Over 5 years, Equity Ratio stood at 0.69 in 2021, then grew by 4.17% to 0.71 in 2022, then rose by 25.15% to 0.89 in 2023, then rose by 0.16% to 0.89 in 2024, then dropped by 1.05% to 0.89 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.89, 0.88, and 0.88 for Q4 2025, Q3 2025, and Q2 2025 respectively.